Fig. 3
From: SLIT2 promoter hypermethylation predicts disease progression in chronic myeloid leukemia
SLIT2 promoter methylation density alterations during disease progression in six paired CML patients. White cycle: unmethylated CpG dinucleotide; Black cycle: methylated CpG dinucleotide. SLIT2 promoter methylation density in CP stage in Patient a-f were 17.3%, 5.3%, 9.7%, 11%, 11.3% and 9%, whereas in AP/BC stage in Patient a-f were 70.7%, 38%, 50.7%, 29.3%, 26% and 33.7% (P = 0.004, Paired T test)